[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK184890A - USE OF ANTI-T-CELL-IMMUNOTOXIN FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF AUTO-IMMUNE DISEASES - Google Patents

USE OF ANTI-T-CELL-IMMUNOTOXIN FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF AUTO-IMMUNE DISEASES Download PDF

Info

Publication number
DK184890A
DK184890A DK184890A DK184890A DK184890A DK 184890 A DK184890 A DK 184890A DK 184890 A DK184890 A DK 184890A DK 184890 A DK184890 A DK 184890A DK 184890 A DK184890 A DK 184890A
Authority
DK
Denmark
Prior art keywords
immunotoxin
auto
cell
preparation
treatment
Prior art date
Application number
DK184890A
Other languages
Danish (da)
Other versions
DK184890D0 (en
Inventor
Patrick J Scannon
Richard C Harmon
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of DK184890D0 publication Critical patent/DK184890D0/en
Publication of DK184890A publication Critical patent/DK184890A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK184890A 1988-02-03 1990-08-02 USE OF ANTI-T-CELL-IMMUNOTOXIN FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF AUTO-IMMUNE DISEASES DK184890A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15174488A 1988-02-03 1988-02-03
PCT/US1989/000440 WO1989006968A1 (en) 1988-02-03 1989-02-03 Therapeutic use of anti-t cell immunotoxin for autoimmune diseases

Publications (2)

Publication Number Publication Date
DK184890D0 DK184890D0 (en) 1990-08-02
DK184890A true DK184890A (en) 1990-10-03

Family

ID=22540082

Family Applications (1)

Application Number Title Priority Date Filing Date
DK184890A DK184890A (en) 1988-02-03 1990-08-02 USE OF ANTI-T-CELL-IMMUNOTOXIN FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF AUTO-IMMUNE DISEASES

Country Status (5)

Country Link
EP (1) EP0397798A4 (en)
JP (1) JPH03503887A (en)
AU (1) AU633251B2 (en)
DK (1) DK184890A (en)
WO (1) WO1989006968A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000583A1 (en) * 1987-07-17 1989-01-26 Xoma Corporation Improved immunotoxin therapies utilizing purified ricin a-chain species
ES2077670T3 (en) * 1988-12-13 1995-12-01 Univ Florida METHODS AND COMPOSITIONS USED FOR EARLY DETECTION AND TREATMENT OF INSULIN DEPENDENT DIABETES MELLITUS.
US5645998A (en) 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
PT93337B (en) * 1989-03-06 1997-01-31 Univ California TEST FOR TREATMENT AND AUTOIMMUNITY DISEASES
US5397702A (en) * 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
IL98932A0 (en) * 1990-07-27 1992-07-15 Univ California Assay,kits and methods based on nk+channel expression
IT1249051B (en) * 1991-02-26 1995-02-11 Italfarmaco Spa IMMUNOTOXIN FROM ANTI-CD5 MONOCLONAL ANTIBODIES
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
ATE249840T1 (en) * 1991-12-13 2003-10-15 Xoma Corp METHOD AND MATERIALS FOR PRODUCING MODIFIED VARIABLE ANTIBODY DOMAIN AND THERAPEUTIC USE THEREOF
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
EP1015496B1 (en) 1997-03-05 2009-06-17 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Divalent anti-t cells immunotoxins and use thereof
AU3654499A (en) * 1998-04-22 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
JP2022536094A (en) * 2019-06-05 2022-08-12 マジェンタ セラピューティクス インコーポレイテッド Therapies that remove T cells
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
EP0232447A1 (en) * 1986-02-13 1987-08-19 Xoma Corporation Lectin immunotoxins
US4731244A (en) * 1985-11-13 1988-03-15 Ortho Pharmaceutical Corporation Monoclonal antibody therapy
EP0256471A3 (en) * 1986-08-15 1989-10-25 Xoma Corporation Cytotoxic conjugates for cancer therapy
JP2581788B2 (en) * 1987-08-17 1997-02-12 アメリカ合衆国 Methods of treating malignant and autoimmune disorders in humans
US5004692A (en) * 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
JPH03503164A (en) * 1988-02-03 1991-07-18 エクソウマ コーポレーション Immunosuppression by anti-pan T-cell immunotoxin compositions

Also Published As

Publication number Publication date
DK184890D0 (en) 1990-08-02
AU633251B2 (en) 1993-01-28
EP0397798A4 (en) 1991-10-30
WO1989006968A1 (en) 1989-08-10
JPH03503887A (en) 1991-08-29
AU3215789A (en) 1989-08-25
EP0397798A1 (en) 1990-11-22

Similar Documents

Publication Publication Date Title
DK184890A (en) USE OF ANTI-T-CELL-IMMUNOTOXIN FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF AUTO-IMMUNE DISEASES
DK215987D0 (en) PHARMACEUTICAL PREPARATIONS OF SYRELABLE SUBSTANCES FOR TILORAL ADMINISTRATION
DK362189D0 (en) PHARMACEUTICAL PREPARATION FOR INTRAVENOES ADMINISTRATION
NO922005D0 (en) PHARMACEUTICAL PREPARATIONS
DK263288A (en) PHARMACEUTICAL PREPARATION OF CEFUROXIM-AXETIL
DK333788D0 (en) PHARMACEUTICAL PREPARATION FOR TREATMENT OF DAMAGED CARTRIC TISSUE
DK149988A (en) STABLE PHARMACEUTICAL PREPARATIONS
DK184087A (en) PHARMACEUTICAL PREPARATIONS WITH IMPROVED BIOTAIL AVAILABILITY
DK413987D0 (en) PHARMACEUTICAL PREPARATIONS
NO872551D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
DK397388D0 (en) DERIVATIVES OF N-AMINOBUTYL-N-PHENYLARYLAMIDS FOR THERAPEUTIC USE AND PROCEDURE FOR THE PREPARATION OF SUCH DERIVATIVES
DK652787A (en) PHARMACEUTICAL PREPARATIONS
DK226488A (en) USE OF ACE INHIBITORS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
NO874200D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
DK635988D0 (en) 1,3-BUTANDIOLACETOACETATE DERIVATIVES AND USE OF 1,3-BUTANDIOLACETOACETATE COMPOUNDS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
DK447887A (en) PHARMACEUTICAL PREPARATIONS
DK298389D0 (en) PHARMACEUTICAL PREPARATION FOR TOPICAL USE INCLUDING AN AMINE-FUNCTIONAL MEDICINE
DK0458855T3 (en) Pharmaceutical preparation for the treatment of tonsillitis
NO873423D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
NO875359D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
NO872233D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
DK500589D0 (en) PHARMACEUTICAL PREPARATION FOR TREATMENT OF LUNGE OBSTRUCTIONS
DK701588A (en) N-HYDROXY-5-PHENYL-2-FURANCARBOXIMIDAMIDES AND ITS USE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
NO883663D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
DK149588D0 (en) XYLOMETAZOLE-CONTAINING PHARMACEUTICAL PREPARATIONS

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment